Dataset Information

The prognostic role of circulating CD8⁺ T cell proliferation in patients with untreated extensive stage small cell lung cancer.

ABSTRACT:

Background

Immunosuppression caused by tumorigenesis may promote tumor progress and invasion. Here, we investigated whether the characteristics of circulating T lymphocyte subtypes in patients with extensive small cell lung cancer (ED-SCLC) can be used as an alternative marker of tumor progression.

Methods

This study included 36 newly diagnosed ED-SCLC patients before treatment and the patients were followed up. 22 age and sex-matched healthy volunteers were selected as control. The percentages and proliferation potential of T lymphocyte subpopulations from peripheral blood were measured.

Results

CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells (Tregs) were elevated in ED-SCLC patients compared with healthy controls (p?=?0.0083). In contrast, the percentages of CD3⁺ and CD3⁺CD4⁺ T cells were significantly lower in SCLC patients (p?+ T cells of SCLC patients was suppressed compared with healthy controls (p?=?0.0058), but not of CD4⁺ T cells (p?=?0.1611). Multivariate analyses showed that the %divided of CD8⁺ T cells is an independent predictor for PFS (HR: 4.342, 95% CI 1.324-14.245; p?=?0.015). The percentages of peripheral Tregs and the degree of chemotherapy or radiotherapy induced lymphopenia negatively correlated with the proliferation of CD8⁺ T cells (p?=?0.0225, r?=?-?0.379; p?=?0.0003, r?=?-?0.464).

Conclusion

The present study indicates that SCLC patients have impaired immunity in peripheral blood, and the proliferation potential of circulating CD8⁺ T cells is a significant predicator for PFS.

SUBMITTER: An N

PROVIDER: S-EPMC6892179 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The prognostic role of circulating CD8<sup>+</sup> T cell proliferation in patients with untreated extensive stage small cell lung cancer.

An Ning N Wang Haoyi H Jia Wenxiao W Jing Wang W Liu Chao C Zhu Hui H Yu Jinming J

Journal of translational medicine 20191203 1

<h4>Background</h4>Immunosuppression caused by tumorigenesis may promote tumor progress and invasion. Here, we investigated whether the characteristics of circulating T lymphocyte subtypes in patients with extensive small cell lung cancer (ED-SCLC) can be used as an alternative marker of tumor progression.<h4>Methods</h4>This study included 36 newly diagnosed ED-SCLC patients before treatment and the patients were followed up. 22 age and sex-matched healthy volunteers were selected as control. T ...[more]

PMID: 31796037

Similar Datasets

Project description:BackgroundNo novel chemotherapeutic combinations have demonstrated superior efficacy to etoposide/cisplatin (EP), a standard treatment regimen for extensive-stage small cell lung carcinoma (ES-SCLC) over the past decade. We aimed to compare the efficacy and safety of belotecan/cisplatin (BP) and EP regimens in chemotherapy- and radiotherapy-naïve patients with previously untreated ES-SCLC.MethodsWe conducted a multi-center, randomized, open-label, parallel-group, phase III clinical study. A total of 157 patients were recruited at 14 centers with 147 patients meeting the inclusion/exclusion criteria and randomized to either BP (n = 71) or EP (n = 76) treatment arms. A non-inferior response rate (RR) in the BP arm, analyzed by intent-to-treat analysis according to Response Evaluation Criteria in Solid Tumors version 1.0 criteria, was used as the primary endpoint. The secondary endpoints were progression-free survival (PFS) and overall survival (OS).ResultsIn the BP arm, one patient had a complete response, 41 had a partial response (PR), and 17 had stable disease (SD). In the EP arm, 35 patients had PR and 28 had SD. The RR in the BP arm was non-inferior to the EP regimen in patients with ES-SCLC (BP: 59.2 %, EP: 46.1 %, difference: 13.1 %, 90 % two-sided confidence interval: -0.3-26.5, meeting the predefined non-inferiority criterion of -15.0 %). No significant differences in OS or PFS were observed between the treatment arms. Hematologic toxicities, including grade 3/4 anemia and thrombocytopenia, were significantly more prevalent in the BP arm than the EP arm.ConclusionsThe RR to the BP regimen was non-inferior to the EP regimen in chemotherapy- and radiotherapy-naïve patients with previously untreated ES-SCLC. Hematologic toxicities were significantly more prevalent in the BP group, indicating that BP should be used with care, particularly in patients with a poor performance status. Further studies assessing PFS and OS are required to validate the superiority of the BP regimen.Trial registrationClinicalTrials.gov identifier NCT00826644 . Date of Registration: January 21, 2009.

Dataset Information

The prognostic role of circulating CD8⁺ T cell proliferation in patients with untreated extensive stage small cell lung cancer.

Background

Methods

Results

Conclusion

Publications

The prognostic role of circulating CD8<sup>+</sup> T cell proliferation in patients with untreated extensive stage small cell lung cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

The prognostic role of circulating CD8+ T cell proliferation in patients with untreated extensive stage small cell lung cancer.

Background

Methods

Results

Conclusion

Publications

The prognostic role of circulating CD8<sup>+</sup> T cell proliferation in patients with untreated extensive stage small cell lung cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

The prognostic role of circulating CD8⁺ T cell proliferation in patients with untreated extensive stage small cell lung cancer.